• Modern aspects of prophylaxis and treatment of the fetus growth retardation syndrome
To content

Modern aspects of prophylaxis and treatment of the fetus growth retardation syndrome

SOVREMENNAYA PEDIATRIYA.2014.4(60):43-45;doi 10.15574/SP.2014.60.43

Modern aspects of prophylaxis and treatment of the fetus growth retardation syndrome

Маkarenko М. V. 
Kiev Meternity Hospital №5

Purpose: to develop the aspects of prophylaxis of the fetus growth retardation syndrome among pregnant women with the fetoplacental insufficiency.

Patients and methods. There were studied the pregnancy passing, birth and perinatal outcomes among 220 patients with the signs of placental insufficiency (according to the ultrasonic diagnostics), without the hemodynamic instability in the system «mother—placenta—fetus», and the risk of the fetal growth retardation development syndrome. The first group consist of 120 patients who got the medical complex directed on the placental dysfunction therapy and the fetus growth retardation prophylaxis, the second one consist of the 100 pregnant women with the risk of the above syndrome who got any prevention treatment. According to this methodic on 14–16 pregnancy week it was appointed the micronized progesterone 200 mg twice a day intravaginal; the combined polyvitamin complex of micro- and macro elements; potassium iodide 200 mg per day; the complex of the polyunsaturated omega73 fatty acids family; the dry water extract of fresh artichoke leaves 2 tablets 3 times a day.

Results: the first group (main) newborns had no severe fetal hypoxia as the comparison group got 13% index. First group children 90 (90%) were born in a satisfactory condition (Apgar scale 8–10 ); in a state of mild asphyxia — 8 (8%); moderate severity rank — 2 (2%); severe rank — 0. The second group of children (the comparison) who were born in an asphyxia state mostly predominated : light rate — 10 (10%); middle — 9 (9%); hard — 12 (12%).

Conclusion: the prevention and treatment conducting of the very syndrome among the patients with the risk group is a reserve for reducing low birth among the children with a low body weight and it improves the medical care for pregnant women and newborns.

Key words: SFRG, prevention, treatment.

REFERENCES 
1. Давыдов АИ, Агрба ИБ, Волощук ИН. 2012. Патогенез патологии прикрепления плаценты: роль факторов роста и других иммуногистохимических маркеров. Вопр гинекол, акушерства и перинатол. 11;1: 48—54.

2. Милованов АП, Ерофеева ЛМ, Золотухина ИА и др. 2011. Морфогенез плаценты человека в I триместре беременности. Морфология. 139;2: 72—76.

3. Стрижаков АН, Игнатко ИВ, Тимохина ЕВ, Белоцерковцева ЛД. 2012. Синдром задержки роста плода. М: 120.

4. Ходжаева ЗС, Мусиенко ЕВ, Сухих ГТ. 2011. Особенности секреции про- и антиангиогенных факторов в I триместре беременности у женщин с привычным выкидышем в анамнезе. Проблемы репродукции. 2: 30—34.

5. Merce LT, Barco MJ, Boer K et al. 2009. Intervillous and uteroplacental circulation in normal early pregnancy: a confocal lases scanning microscopical study. Am J Obst Gynecol. 200;3: 315—320.

6. Maglione D, Guerriero V, Viglietto G et al. 2012. Two alternative mRNAs coding for the angiogenic factor, placental growth factor (P1GF), are transcribed from a single gene of chromosome 14. Oncogene. 8: 925—931.

7. World Health Organization (WHO). Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva. WHO. 2011.